95 results about "Cellulose acetate phthalate" patented technology

The invention relates to probiotic microcapsules as well as a preparation method and application thereof. The probiotic microcapsules comprise a core material and a wall material, wherein the core material is probiotics; the outer layer of the wall material is coated with chitosan; the wall material is prepared from an aqueous solution containing a natural polymer material and a freeze-drying protection agent; the freeze-drying protection agent comprises one or more of glucose, fructose, sucrose, lactose, trehalose, soluble starch, glycerin, mannitol, Arabic gum, dextran 40 and skim milk; the natural polymer material comprises one or more of gellan gum, xanthan gum, k-carrageenan, sodium alginate, cellulose acetate phthalate or gelatin; in the aqueous solution, the volume fraction of the freeze-drying protection agent is 4.0%-20.0% and the volume fraction of the polymer material is 0.5%-5.0%. The probiotic microcapsules can keep excellent acid resistance and storage stability before and after being freeze-dried.

A composition for controlled delivery of at least one active substance into an aqueous medium by erosion at a preprogrammed rate of at least one surface of the composition, comprising a matrix comprising the active substance, the matrix being erodible in the aqueous medium in which the composition is to be used, and a coating having at least one opening exposing at least one surface of said matrix, the coating comprising a first cellulose derivative which has thermoplastic properties and which is substantially insoluble in the aqueous medium in which the composition is to be used, and at least one of a second cellulose derivative which is soluble or dispersible in water, a plasticizer, and a filler. The coating is a coating which crumbles and/or erodes upon exposure to the aqueous medium such as a body fluid. The first cellulose derivative may be, e.g., ethylcellulose, cellulose acetate, cellulose propionate or cellulose nitrate, and the second cellulose derivative may be, e.g., methylcellulose, carboxymethylcellulose or salts thereof, cellulose acetate phthalate, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose or hydroxymethylpropylcellulose.

A soft, pliable cellulose acetate phthalate (CAP)—hydroxypropyl cellulose (HPC) composite film is provided which is generated by casting from organic solvent mixtures containing ethanol. The film rapidly reduces the infectivity of several sexually transmitted disease pathogens, including the human immunodeficiency virus (HIV-1), herpesvirus (HSV), non-viral sexually transmitted disease pathogens (such as Neisseria gonorrhoeae, Haemophilus ducreyi, Chlamydia trachomatis and Treponema pallidum) and bacteria associated with bacterial vaginosis (BV). The film is converted into a gel/cream and thus does not have to be removed following application and use. In addition to being a topical microbicide, the film can be employed for the mucosal delivery of pharmaceuticals other than cellulose acetate phthalate.

The invention relates to an enteric-coated tilmicosin slow-release micro-capsule preparation and a preparation method thereof and belongs to the field of tilmicosin preparations. The enteric-coated tilmicosin slow-release micro-capsule preparation provided by the invention comprises an inner core layer and a coating layer, wherein the inner core layer comprises tilmicosin raw powder and an auxiliary material; the auxiliary material comprises one or more than one of stearic acid, glycerin monostearate, stearyl alcohol, saturated triglyceride, monoglyceride and paraffin; and the coating layer is made from one or more than one of cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, acrylic resin, polyvinyl acetate phthalate and acetic hydroxypropyl methylcellulose succinate. The preparation method comprises the following steps of: carrying out primary coating on the tilmicosin raw powder and the auxiliary material, carrying out secondary coating by using the materials of the coating layer, and drying to obtain the finished product. According to the invention, the tilmicosin is coated by using high polymer materials and the coated tilmicosin micro-capsule is undissolved in acid environment and slowly dissolved in alkaline environment of enteric canal, so that the purpose of slow release is achieved and the action time of the tilmicosin is prolonged.

An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulos- e phthalate, and (b) at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose; or a pectin, such as an apple pectin. The device is prepared by a combination of foaming, freezing and freeze-drying processes.

The invention discloses an ursolic acid solid dispersion and a preparation method thereof. The formula of the ursolic acid solid dispersion comprises ursolic acid and a carrier material; the mass ratio of the ursolic acid to the carrier material is 1:2 to 1:20; and the carrier material is one or more of PEG6000 (polyethylene glycol 6000), povidone k29/33, hypromellose E5, polyving alcohol, poloxamer 68, GELUCIRE 50/13, polyacrylic resin EPO, polyacrylic resin L 100-55, povidone-vinyl alcohol, hypromellose AS-HG, hypromellose AS-LG, hypromellose AS-MG, low substituted hypromellose, hypromellose phthalate, cellulose acetate phthalate, glucan, polyoxyethylene, polyoxyethylene stearates and polyvinyl acetate phthalate. The preparation method comprises the following steps: dissolving the ursolic acid and the carrier material into an organic solvent according to the formula; removing the organic solvent; and grinding. The ursolic acid solid dispersion has good solubility and has high bioavailability.

A hemostatic device comprising (i) a carrier comprising at least one component selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate, polymethacrylate-based polymers, and derivatives, salts, copolymers or combinations thereof; and (ii) thrombin

New compositions for forming films for use in optical devices are provided. The compositions comprise a cellulose and a crosslinking agent dissolved or dispersed in a solvent system. Preferred celluloses are cellulose esters such as cellulose acetates, cellulose triacetates, cellulose acetate phthalates, and cellulose acetate butyrates. Preferred crosslinking agents are triazines such as those derived from melamine and benzoguanamine. The inventive compositions can be used to form, for example, protective and/or compensation films for use in polarizing plates.

The invention relates to a novel enteric sustained-release zinc oxide-oligosaccharide composite pellet for feed and a preparation method thereof. The novel enteric sustained-release zinc oxide-oligosaccharide composite pellet for feed comprises: by weight, 38 to 75% of zinc oxide powder, 15 to 35% of oligosaccharide, 2 to 14% of starch, 1.5 to 5.5% of cellulose acetate-phthalate, 0.05 to 0.1% of sodium alginate, 4.5 to 9.5% of talcum powder, and 0.15 to 0.5% of diethyl phthalate. The novel enteric sustained-release zinc oxide-oligosaccharide composite pellet for feed has the advantages of good effects of dissolution in the enteric canal and good treatment effects.

Methods for maintaining a low vaginal pH, preventing the propagation of toxic shock syndrome toxin 1 production during menstruation, preventing the shedding and dissemination of a herpesvirus and treating herpes lesions comprising administering to a human a formulation comprising a pharmaceutically effective amount of an insoluble micronized form of cellulose acetate phthalate or a cellulose acetate phthalate film or a cellulose acetate phthalate porous sponge. Also a method of treating Candida albicans infection comprising administering to a human female a pharmaceutically effective amount of a composition comprising micronized cellulose acetate phthalate and miconazole nitrate.

The invention provides a gingko leaf sustained release formulation and preparation process, wherein the formulation comprises total flavone glucoside extracted from ginkgo leaves as active components, slow release material coated on the outer layer of the reactive component and adjuvant by the weight ratio of 40-50:50-70:290-300, and is prepared into slow release micro-pellet with different releasing rate, the slow release material can be any one to four of acrylic acid resin, methyl hydroxypropylcellulose, ethyl cellulose, cellulose acetate phthalate, and polyvinylpyrrolidone.

The invention discloses a method for microencapsulating pitaya peel pigment. The method comprises the following steps: A, dissolving a core material (namely pitaya peel pigment) into water, with that, obtaining a core material solution for standby, wherein the concentration of the core material solution is 95-98 percent; B, preparing a wall material, taking and mixing the wall material, and adding cellulose acetate phthalate into the wall material, with that, obtaining a wall material solution for standby; C, mixing the core material solution, the wall material solution, the water and an emulsifier, performing high-pressure homogenization to obtain emulsion, wherein the solid content of the emulsion is 15-30 percent; performing spray drying to the emulsion to obtain the microencapsulated pitaya peel pigment. According to the invention, via microencapsulating the pitaya peel pigment, the stability of the pitaya peel pigment and the solubility of the pitaya peel pigment in a fat-soluble medium are improved, and the technical effect of the food industry application of the pitaya peel pigment is expanded.

The invention discloses a polyvinylidene fluoride composite film, the raw materials of which include by weight: 20-30 parts of polyvinylidene fluoride, 1-5 parts of poly(acrylonitrile-acrylic acid-N-vinylpyrrolidone) terpolymer, 1-3.5 parts of acrylamide, 0.5-2 parts of carboxybetaine methacrylate, 1-5 parts of cellulose acetate phthalate, 0.5-2 parts of inorganic particles, 2-3.5 parts of polyvinylpyrrolidone, 55-70 parts of solvent 0.5-1.5 parts of polyethylene glycol monostearyl ether; the inorganic particles are mesoporous silica, zeolite molecular sieve loaded with silver ions, nano-calcium carbonate, nano-zinc oxide, modified montmorillonite, and nano-zirconia. Mixture in weight ratio 1‑5:2‑6:1‑5:3‑10:1‑4:2‑5. The polyvinylidene fluoride composite membrane proposed by the invention has high strength, excellent weather resistance, antibacterial and stain resistance.

The invention relates to a pharmaceutical composition comprising a plurality of controlled-release coated microparticles each comprising a floating core, on the surface of which is deposited a layer containing at least one active principle, said layer being covered with a controlled-release coating, characterized by the fact that said floating core is composed of cellulose acetate phthalate and has an apparent density of less than or equal to 0.6 g/mL and said coated microparticles have a density of less than or equal to 0.7 g/mL.

The invention discloses a gel polymer electrolyte with blended cellulose and a preparation method and application of the gel polymer electrolyte and belongs to the field of lithium-ion batteries. Themethod comprises the following steps of dissolving poly(vinylidene fluoride-hexafluoropropylene) and cellulose acetate phthalate into acetone and stirring until a polymer is completely dissolved and forms a colorless transparent gel solution, namely a blended polymer solution; immersing a blank non-woven fabric into the blended polymer solution, quickly pulling up the blank non-woven fabric aftera few seconds, drying in the air and then drying in vacuum; preparing a porous gel polymer membrane with the blended cellulose; and dropwise adding an electrolyte solution on the upper and lower surfaces of the gel polymer membrane to obtain the gel polymer electrolyte with the blended cellulose when the battery is assembled. The gel polymer electrolyte is simple in preparation technology, short in time, high in production efficiency, high in mechanical strength and excellent in cycling stability, and the obtained polymer membrane has excellent absorption performance and liquid holding capacity, and has good ionic conductivity and interface stability.

The present invention provides a cellulose long chain fatty acid phthalate and a synthesis preparation method therefor. The cellulose long chain fatty acid phthalate is prepared by carrying out reaction on a fatty acylating agent and a homogeneous cellulose DMAc/LiCl solution at 50 DEG C to 80 DEG C for 2-12 hours to prepare a cellulose long chain fatty acid ester; and then carrying out reaction on the cellulose long chain fatty acid ester and phthalic anhydride and a catalyst at room temperature, and washing and drying the product. Presence of long chain fatty ester groups in the cellulose long chain fatty acid phthalate greatly improves the workability of cellulose acetate phthalate (CAP) and overcomes the dependency of the existing cellulose acetate phthalate (CAP) on plasticizers in terms of workability. The technical scheme of the present invention further has the technical advantages of mild process condition, easy implementation, no to-be-separated intermediates during the reaction, short preparation time, recyclable cellulose DMAc/LiCl solution and the like.

Disclosed is a method for preparing aceclofenac enteric microcapsules, comprising dissolving eudragit II, hydroxypropylmethylcellulose phthalate (HPMCP) or cellulose acetate phthalate in acetone to acquire a solution A; then adding aceclofenac powder into the solution A and fully dissolving the aceclofenac powder to obtain a solution B, and acquiring a primary emulsion by placing the solution B in a flask and stirring; adding span 80 into liquid paraffin and fully stirring; adding the primary emulsion into the well-stirred liquid paraffin, heating up to 75 DEG C gradually while stirring, and acquiring microcapsules by stirring continuously while preserving the temperature; and washing the microcapsules by using n-hexane three times after filtering and drying to acquire the finished microcapsules. According to the invention, the aceclofenac slow-release enteric microcapsules are prepared by using a property that decomposition of a capsule wall material is influenced by pH values. Through controlling the capsule wall material, the following effects can be achieved: drugs are sent directionally to the small intestine and released slowly to gentle the plasma concentration, prolong the action time, and improve the curative effect; the dosing frequency can be reduced and the plasma concentration is maintained in the body; and an adverse reaction in the gastrointestinal tract is reduced effectively and patient compliance is also improved effectively.

The invention discloses an ivermectin controlled-release capsule and a preparation method and application thereof. The ivermectin controlled-release capsule comprises, by mass, 0.1-1% of ivermectin raw material, 20-60% of water-soluble carrier and 30-70% of enteric-soluble wrapping material, the water-soluble carrier is one or multiple of hydroxypropyl-beta-cyclodextrin, methyl-beta-cyclodextrin,HPMC, PVP, PEG, poloxamer 188, mannitol, D-alpha-tocopherol PEG 1000 succinate, cholate/phospholipid mixed micelle, polyethylenediamine dendritic polymer, phospholipid or cholesterol, and the enteric-soluble wrapping material is one or multiple of hydroxypropyl methyl cellulose phthalic acid, acrylic resin II, acrylic III, cellulose acetate phthalate, polyethylene diacetate phthalate or hydroxypropyl methyl cellulose acetate succinate. The ivermectin controlled-release capsule has the advantage of outstanding acid resistance, enables drug to reach intestinal tracts to be disintegrated and released, remarkably improves bioavailability and has remarkable treatment effect.

The invention relates to edible medicinal ink which comprises pigments, solvents and a binder, wherein the binder is cellulose acetate phthalate and/or cellulose acetate succinate. The edible medicinal ink uses the cellulose acetate succinate and/or the cellulose acetate phthalate as the binder, and the pigments in various colors and pharmaceutically applicable solvents such as ethanol, propanol or butanol and the like are used as auxiliary materials, thereby forming the edible medicinal ink with excellent quality. The performance of the edible medicinal ink for word printing on the surfaces of medicinal hollow capsules, tablets and the like is better than that of similar products, and the edible medicinal ink can well meet the requirements on word printing on the capsules against differences of word printing equipment, differences in gelatin sources and quality, different companies, different regions and different formulas of the hollow capsules.

There are manufactured an enteric capsule comprising: a seamless capsule consisting of a capsule fill and a shell layer; and an enteric coating layer on the shell layer, the enteric coating layer comprising one selected from a methacrylic acid-based polymer, polyvinyl acetate phthalate, organic acid ester of hydroxypropylmethylcellulose, carboxymethylethylcellulose, and cellulose acetate phthalate; and an enteric seamless capsule further comprising a subcoating layer between the shell layer of the seamless capsule and the enteric coating layer, the subcoating layer consisting of hydroxypropylcellulose and the like. The enteric seamless capsule has acid resistance and also enables controlled dissolution for each application site in the body.

The invention discloses a preparation method and application of a chloroprene-rubber-adding building material. The method comprises the following steps of processing Portland cement, perlite powder and sepiolite into powder through ball milling; performing calcination; then, adding modified carboxyl polyester resin and a mixture of polyacrylamide, cellulose acetate-phthalate and polyphenyl thioether subjected to ultrasonic processing for simultaneous heating reaction; then, performing a series of specific processes such as mixing, vulcanization, crushing, stirring, injection molding and heat insulation aging to obtain a finished product of the building material. The prepared building material has the advantages that the toughness is sufficient; the intensity is high; good application prospects are realized. Meanwhile, the invention also discloses application of the building material prepared by the preparation method to building wall body materials.